Why EDIT? Editas Medicine, Inc. Analysis, Price & AI Insights | Whystock
EDIT
$2.90-0.10 (-3.33%)
Market ClosedLast close May 1
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.